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measured prospectively from the societal perspective for
90 days after randomization; the primary outcome was
survival at 90 days. The cost and mortality differences
were estimated using multivariate analysis.
RESULTS: A total of 221 patients received the gender-
appropriate dosage of tirilazad and 235 received vehicle.
The cost difference was $11,937 (95% CI $5898–$17,976)
and the effects difference was 0.147 (95% CI 0.064–0.215)
deaths averted. The cost-effectiveness ratio was $81,204
per death averted (95% CI 48,393–141,679).
CONCLUSIONS: This study is one of the first economic
meta-analyses using primary data from multiple phase III
studies. We will translate the cost-effectiveness ratio of
$81,204 per death averted into a ratio of cost per quality-
adjusted life-years (QALYs) saved so that tirilazad’s
value for its cost can be assessed. QALYs will be esti-
mated using a decision model based on newly acquired
data from a registry of SAH patients from Denmark.
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The efficacy of the GPIIb/IIIa antagonist abciximab in per-
cutaneous coronary intervention (PCI) patients has been
established through randomized clinical trials. However,
the cost-effectiveness of abciximab in these patients has
not been adequately addressed.
OBJECTIVE: The study purpose was to estimate the cost
per life-year saved of abciximab in PCI patients.
METHODS: The relative risk of mortality with abcix-
imab was estimated based on a meta-analysis of six clini-
cal trials with 6537 patients. One-year mortality and ex-
pected years of survival in PCI patients were based on
published data. The incremental cost of abciximab was
estimated based on bills for the initial hospitalization col-
lected in the EPILOG trial. Since the costs and outcomes
were negatively correlated, the box method was used to
estimate confidence interval around the cost-effectiveness
estimate.
RESULTS: The meta-analysis showed that abciximab
significantly reduced risk of mortality in PCI patients,
with a hazard ratio of 0.64 (95% CI 0.49, 0.85, p 
0.002). One-year mortality in control patients was esti-
mated to be 3.1%, and the expected survival in patients
alive 1 year after intervention was at least 14 (11.3 dis-
counted) years. The incremental cost of abciximab was
$583 ($61, $1116) and years of life saved were 0.125
(0.05, 0.18) leading to a cost per life-year saved of $4664
($339, $22,320). Cost per life-year saved assuming no
cost offset with abciximab was $11,675.
CONCLUSIONS: The cost-effectiveness ratio for abcix-
imab treatment in PCI patients falls within commonly ac-
cepted thresholds; hence abciximab reduces mortality in
PCI patients at a favorable incremental cost.
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Vietnam is in a tropical region where malaria is consid-
ered a public health problem. Phuoc Long Hospital is a
district hospital located in the southeast 160 km from Ho
Chi Minh City, with 108 beds, and where there are ma-
larial patients year-round. Cost-effectiveness approach
will guide the government to choose the right regimen
under its limited budget.
OBJECTIVE: The purpose of this study was to compare
the cost-effectiveness of two commonly used antimalarial
drug regimens: Quinine plus Doxycycline (A-regimen)
and Artemisinin plus Doxycycline (B-regimen) in govern-
ment perspective.
METHODS: In this study 171 uncomplicated Falci-
parum inpatients at Phuoc Long Hospital were studied.
Of those, 84 patients were randomized treated by A-regi-
men and 87 patients by B-regimen. It was a non-experi-
ment Cohort study. The data were collected during Feb-
ruary and June 1997.
RESULTS: Two groups of studied population were identi-
cal in terms of sociodemographic variables as well as ill-
ness pattern. Three components of cost were different be-
tween these two regimens; cost of antimalarial drug, labor
cost, and cost of symptomatic treatment. The cost of drug
for A-regimen was 10,600 VND ($0.921), while for B-reg-
imen was 12,300 VND ($1.070). Of patients who received
A-regimen, 61.9% had side effects which need symptom-
atic treatment that cost on average 793.9 VND per pa-
tient. Total costs per patient in government perspective of
A-regimen was 340,570.7 VND ($29.615) and B-regimen
was 341,567.6 VND ($29.702). The effectiveness of
A-regimen was found to be 81.7% while of B-regimen was
92.6%. The cost-effectiveness ratio of A-regimen was
416,855.2 VND ($36.3) compared to 368,863.5 VND
($32.1) of B-regimen. Thus, B-regimen was more cost-
effective than A-regimen.
CONCLUSION: Based on the results of this research, it is
suggested that, B-regimen could be chosen as first line
treatment for uncomplicated Falciparum patients in Phuoc
Long Hospital in Vietnam.
